Use of lmo7 inhibitors in the manufacture of a product for treating glioma

By developing a nucleic acid molecule and lentiviral vector delivery system targeting the LMO7 gene, the problem of inhibiting cell proliferation and migration in the treatment of glioma has been solved, achieving a highly efficient and low-toxicity therapeutic effect.

CN117398403BActive Publication Date: 2026-05-19SHANGHAI YIBEIRUI BIOMEDICAL SCIENCE & TECHNOLOGY CO LTD
3 Cites 0 Cited by

Patent Information

Application Number
CN202311372095.5
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2023-10-23
Publication Date
2026-05-19
Estimated Expiration
2043-10-23

AI Technical Summary

Technical Problem

Current treatments for gliomas are often ineffective in inhibiting the proliferation and migration of tumor cells, and also present the problem of drug toxicity and side effects.

Method used

Using the LMO7 gene as a target, we developed LMO7 inhibitors, including nucleic acid molecules such as double-stranded RNA or shRNA, which were delivered to glioma cells via lentiviral vectors to reduce the expression of the LMO7 gene and inhibit cell proliferation and migration.

Benefits of technology

It significantly inhibits the proliferation and migration of glioma cells, reduces LMO7 gene expression, improves treatment efficiency, reduces drug toxicity and side effects, and is a high-throughput and highly reproducible procedure.

✦ Generated by Eureka AI based on patent content.
Patent Text Reader

Abstract

The present application relates to the field of molecular biology, in particular to the use of LMO7 inhibitor in the preparation of glioma treatment products, the present application adopts the siRNA obtained by RNAi method or the nucleic acid construct containing the siRNA sequence, the lentivirus, the expression of human LMO7 gene is down-regulated, and the proliferation and migration of glioma cells can be effectively inhibited, therefore the LMO7 inhibitor of the present application can be used in the preparation of the drug for treating brain glioma, thereby treating brain glioma, and opening up a new direction for brain glioma treatment.
Need to check novelty before this filing date? Find Prior Art